I am a physician-scientist who holds a clinical appointment on the Gastrointestinal Oncology Service and a research appointment in the Cancer Biology and Genetics Program. I study basic mechanisms of cancer metastasis, with the aim of turning metastasis into a treatable condition. My laboratory utilizes the zebrafish — an unusual but increasingly appreciated animal that helps us to understand the genetic changes that allow cancers to grow and metastasize. One of the reasons we use a fish to study cancer is that it allows us to investigate thousands of potential drugs that could be used to treat metastasis in a way that cannot be done in other laboratory settings. Much of my work centers on the markedly aggressive forms of pancreatic cancer and melanoma. These diseases are notoriously difficult, if not impossible, to treat once they have metastasized and are associated with extremely low survival rates. The understanding of metastasis in these two diseases could have far-reaching implications for the way we think about treating virtually any form of metastatic cancer.
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicare and New York State Medicaid also provide benefits for care at MSK.Learn more